The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the Virginia Commonwealth University, the Dirección General de Epidemiología del Ministerio de Salud (Peru) or Instituto de Investigaciones Clínicas de la Universidad Nacional Mayor de San Marcos (Peru).
Clinical dermatology ● Original article
Endemic pemphigus foliaceus in the Peruvian Amazon
Version of Record online: 21 MAY 2013
© 2013 British Association of Dermatologists
Clinical and Experimental Dermatology
Volume 38, Issue 6, pages 594–600, August 2013
How to Cite
Ortega-Loayza, A. G., Ramos, W., Gutierrez, E. L., Jimenez, G., Rojas, I. and Galarza, C. (2013), Endemic pemphigus foliaceus in the Peruvian Amazon. Clinical and Experimental Dermatology, 38: 594–600. doi: 10.1111/ced.12029
Conflict of interest: none declared.
- Issue online: 10 JUL 2013
- Version of Record online: 21 MAY 2013
- Manuscript Accepted: 15 MAY 2012
Endemic pemphigus foliaceus (EPF) is an organ-specific blistering disease of the epidermis characterized by the presence of IgG autoantibodies, specifically desmoglein (Dsg)1. This condition has been reported particularly in Brazil, Colombia, Tunisia and Peru.
To characterize the humoral response against Dsg1 and Dsg3 autoantibodies of patients with EPF from the Peruvian Amazon region.
Blood samples were collected from 16 patients with a clinical diagnosis of EPF, and tested using indirect immunofluorescence (IIF), immunoprecipitation and ELISA (for IgG and its subclasses against Dsg1 and IgG against Dsg3).
Autoantibodies against the intercellular spaces were detected by IIF in 82.5% and 87.5% of patients, using normal human skin and monkey oesophagus, respectively. Sera from all patients immunoprecipitated recombinant Dsg1, and three serum samples immunoprecipitated recombinant Dsg3 (6.25%). Using ELISA, anti-Dsg1 antibodies were detected in 13 patients (81.25%), and both IgG1 and IgG2 antibodies against Dsg1 in 12 patients (75%). All patients were positive for IgG4 autoantibodies, and only one patient was positive for IgG3 autoantibodies (6.25%). Anti-Dsg3 antibodies were detected in five patients (31.25%).
EPF from Peru shares epidemiological, clinical and immunological characteristics with other forms of EPF that have been described in South America.